Biotron Share Price and Company Fundamentals
Last traded: Last Friday at 5:25 AM
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
Key Metrics
PE ratio
-
PB ratio
9.17
Dividend yield
Beta
-1.97
Market cap
$38.61M
Enterprise value
$34.4M
Company profile
| Primary activities | Conduct clinical trials, research and commercialisation of a number of anti-viral (HCV and HIV) drugs developed from biomedical projects researched at the John Curtin School of Medical Research. |
|---|---|
| Industry / Sector | Biotechnology / Healthcare |
| Website | http://www.biotron.com.au |
| Mailing address | 66 Hunter Street Level 2 Sydney NSW 2000 Australia |
| Phone / Fax | 61 2 9300 3344 / 61 2 9221 6333 |
| Share registry | COMPUTERSHARE INVESTOR SERVICES PTY LIMITED |
Dividends
Biotron does not pay dividends.
Company Executives
As of Sep 2021, following are the company executives and directors listed on Biotron.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. | CEO, MD & Exec. Director | 365.48k | |
| Mr. Peter James Nightingale B.Econ, CA | Company Sec. | 63 | 84k |
| Dr. Stephen L. Becker M.D. | Chief Medical Officer |
Profitability and management effectiveness
Profit margin
-218.50%
Operating margin
-219.19%
Return on assets
-32.96%
Return on equity
-58.96%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Biotron is 38.61M and its enterprise value is 34.4M. The enterprise value to revenue ratio of BIT is 23.53.
Companies similar to Biotron (BIT)
Biotron (ASX:BIT) Frequently Asked Questions
1. What is Biotron's Stock Symbol?
Biotron trades on ASX under the ticker symbol "BIT".
2. What is Biotron's stock price today?
One share of BIT stock can currently be purchased for approximately $0.055.
3. How can I contact Biotron?
Biotron's mailing address is 66 Hunter Street Level 2 Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 9300 3344.
4. What is Biotron's official website?
The official website of Biotron is http://www.biotron.com.au.
5. Which share registry manages Biotron's stock?
Biotron's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.